Stomach Cancer Treatment Market Size, Share | Report 2022-2030
The global stomach cancer treatment market was surpassed at USD 3.94 billion in 2021 and is expected to hit around USD 11.5 billion by 2030, growing at a CAGR of 12.64% from 2022 to 2030.
Report Highlights
Increasing uptake of immunotherapy and targeted therapy coupled with the launch of new drugs is expected to fuel growth.
According to Globocan, the incidence of gastric cancer in 2020 was around 1.1 million, which is expected to increase to 1.42 million by 2030. Increasing knowledge regarding the molecular basis of the disease has led to a rise in the number of targeted drugs and immunotherapy drugs being developed and launched in the market. HER-2 targeted drugs such as Herceptin have been available in the market since 2010. Another targeted drug, Cyramza, which is a VEGF targeting monoclonal antibody, has been available since 2014. EGFR and PD-1 targeted drugs and immunotherapies are currently being developed for the treatment of gastric cancer.
The approval and subsequent launch of drugs in the clinical pipeline are also expected to drive the gastric cancer therapy market. For instance, in March 2021, the NMPA approved Eli Lilly and Innovent Biologics’ drug Sintilimab, a PD-1 inhibitor, for the treatment of gastric or gastroesophageal junction adenocarcinoma in China. Furthermore, in May 2020, the U.S. FDA granted the orphan drug designation to Enhertu for the treatment of gastric cancers. Subsequently, in January 2021, the U.S. FDA approved Enhertu for the treatment of advanced or metastatic forms of the disease.
Patent expiry of key drugs such as Herceptin and subsequent launch of biosimilars are expected to restrain the growth of the gastric cancer therapy market. Additionally, lesser adoption of targeted therapy due to high costs might hamper the growth of the market. For instance, Cyramza was not considered cost-effective as compared to other drugs. It was rejected by NICE due to a lack of cost-effectiveness in England. Furthermore, the product was rejected for reimbursement in France due to a lack of additional benefits compared to the clinically relevant comparators.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 3.94 billion |
| Revenue Forecast by 2030 | USD 11.5 billion |
| Growth rate from 2022 to 2030 | CAGR of 12.64% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Treatment type, disease indication, route of administration, drug class, distribution channel, region |
| Companies Covered |
Novartis AG; Pfizer, Inc.; Mylan N.V.; F. Hoffmann La Roche Ltd.; Eli Lilly and Company; Merck & Co., Inc.; Teva Pharmaceutical Industries Ltd.; Celltrion Healthcare Co., Ltd; Samsung Bioepis; Bristol Myers Squibb Company |
Treatment Type Insights
The chemotherapy segment held the largest revenue share of the gastric cancer therapy market of over 40.2% in 2021 due to a high prescription rate. First-line therapy for patients diagnosed in early stages is generally surgery with adjuvant chemotherapy or neoadjuvant chemotherapy. An article suggests that around 65% of patients with advanced cancers, 85% with lymph node metastases, and 40% with metastatic disease undergo surgical procedures. Chemotherapy can be given either as neoadjuvant chemotherapy or adjuvant chemotherapy to shrink the tumor or kill the cancerous cells. Based on treatment type, the market is segmented into chemotherapy, immunotherapy, and targeted therapy.
The targeted therapy segment is expected to account for the largest share of the gastric cancer drugs market by the end of the forecast period owing to the product launches, recent advancements in the field of targeted therapy, and a robust clinical pipeline. On the other hand, the patent expiry of Herceptin is restraining the growth of this segment.
The immunotherapy segment is expected to witness the fastest growth over the forecast period due to increasing product launches. For instance, in March 2020, Bristol-Myers Squibb Company’s drug for Opdivo received approval for stomach cancer treatment in China. Another key immunotherapy drug approved is Keytruda. Immunotherapy in combination with chemotherapy is generally used as a third-line or fourth-line treatment option.
Route of Administration Insights
The injectable segment dominated the market for gastric cancer therapy market with a revenue share of over 90.09% in 2021. Most of the chemotherapy drugs, targeted drugs, and immunotherapy drugs are available in injectable form leading to the dominance of this segment.
The oral segment is expected to grow at the highest rate over the forecast period. In order to overcome the cumbersome IV administration, many companies are developing oral chemotherapy agents for treatment. For instance, Ascelia Pharma is currently conducting Phase II clinical trials for the use of Oncoral (oral irinotecan) for the treatment of gastric cancer.
Drug Class Insights
The other drug classes segment accounted for the largest share of the gastric cancer drugs market of over 60.33% in 2021. Chemotherapy currently accounts for the largest share in the others segment. Chemotherapy is still widely used as a first-line treatment in countries such as China and India, which have the highest prevalence of gastric cancer.
The PD-1/PD-L1 inhibitors segment is expected to expand at the fastest CAGR during the forecast period. The approval and increasing uptake of Keytruda and Opdivo for gastric cancer therapy are driving this segment. In addition to this, the NMPA approved TYVYT (sintilimab) for the treatment of gastric cancer in China in June 2021.
Distribution Channel Insights
The specialty and retail pharmacies segment dominated the gastric cancer therapy market in 2021 with a revenue share of over 65.05%. Most of the drugs used for the treatment of gastric cancer are distributed via specialty pharmacies as they have to be stored and distributed under specific conditions. For instance, in June 2021, Blueprint Medicines recently selected PANTHERx Rare Pharmacy and Biologics, by McKesson, for the distribution of its GIST treatment drug AYVAKIT. Based on distribution channel, the market has been segmented into hospital pharmacies, specialty and retail pharmacies, and others.
The hospital pharmacies segment accounted for the second-largest share in 2021. Most of the patients with gastric cancer undergo inpatient administration of treatment in developing nations. This is one of the major factors fueling the growth of this segment.
Disease Indication Insights
The GC/GEJC segment held the largest revenue share of over 85.47% in 2021. High disease burden coupled with a large number of approved products for this indication is contributing to the growth of this segment. According to Globocan, the 5-year prevalence of stomach cancer was around 1.8 million in 2020. Based on disease indication, the market is segmented into gastric cancer/gastroesophageal junction cancer (GC/GEJC) and gastrointestinal stromal tumors.
The gastrointestinal stromal tumors (GISTs) segment is estimated to witness moderate growth during forecast period. GISTs are rare cancers and around 4,000 to 6,000 new cases are diagnosed every year in the U.S. Targeted drugs such as Ayvakit, Gleevec, Stivarga, and Qinlock are used for the treatment of GISTs.
Regional Insights
Asia Pacific dominated the gastric cancer therapy market in 2021 with a revenue share of over 55.02%. This is mainly due to the higher prevalence of gastric cancer in this region. For instance, in 2020, the number of new cases in Japan was around 138,000, and in China, it was around 479,000. In countries such as China, chemotherapy is still the most preferred treatment option, however, the presence of a strong product pipeline and the expected approval of the products will boost the regional growth over the forecast period. For instance, in September 2021, AstraZeneca and Daiichi Sankyo Company have dosed the first HER-2 positive gastric cancer patient in Phase II trials of Enhertuin China.
Europe is estimated to witness considerable growth over the forecast period due to increasing investments in the development of advanced treatment options and rising target patient population. For instance, in October 2021, the European Commission approved Bristol Myers Squibb’s Opdivo for the treatment of gastrointestinal junction cancer.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Stomach Cancer Treatment Market
5.1. COVID-19 Landscape: Stomach Cancer Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Stomach Cancer Treatment Market, By Treatment Type
8.1. Stomach Cancer Treatment Market, by Treatment Type, 2022-2030
8.1.1. Immunotherapy
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Targeted Therapy
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Chemotherapy
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Radiation Therapy And Surgery (Qualitative Analysis Only)
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Stomach Cancer Treatment Market, By Disease Indication
9.1. Stomach Cancer Treatment Market, by Disease Indication, 2022-2030
9.1.1. Gastric Cancer/Gastroesophageal Junction Cancer
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Gastrointestinal Stromal Tumors
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Snacks
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Stomach Cancer Treatment Market, By Route of Administration
10.1. Stomach Cancer Treatment Market, by Route of Administration, 2022-2030
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Injectable
10.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Stomach Cancer Treatment Market, By Drug Class
11.1. Stomach Cancer Treatment Market, by Drug Class, 2022-2030
11.1.1. PD-1/PD-L1 Inhibitors
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. HER2 Antagonists
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. VEGFR2 Antagonists
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Stomach Cancer Treatment Market, By Distribution Channel
12.1. Stomach Cancer Treatment Market, by Distribution Channel, 2022-2030
12.1.1. Hospital Pharmacies
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Specialty & Retail Pharmacies
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Others
12.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Stomach Cancer Treatment Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.1.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
13.1.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.1.4. Market Revenue and Forecast, by Drug Class (2017-2030)
13.1.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.1.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
13.1.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.1.6.4. Market Revenue and Forecast, by Drug Class (2017-2030)
13.1.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.1.8. Rest of North America
13.1.8.1. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.1.8.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
13.1.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.1.8.4. Market Revenue and Forecast, by Drug Class (2017-2030)
13.1.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.2.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
13.2.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.4. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.2.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
13.2.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.7. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.8. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.2.9.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
13.2.9.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.10. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.11. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.2.12.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
13.2.12.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.12.4. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.2.14.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
13.2.14.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.2.14.4. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.15. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.3.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
13.3.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.4. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.3.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
13.3.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.6.4. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.3.8.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
13.3.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.8.4. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.9. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.3.10.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
13.3.10.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.10.4. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.10.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.3.11.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
13.3.11.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.3.11.4. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.11.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
13.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.4. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.4.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
13.4.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.6.4. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.4.8.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
13.4.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.8.4. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.9. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.4.10.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
13.4.10.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.10.4. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.10.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.4.11.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
13.4.11.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.4.11.4. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.11.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
13.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.5.4. Market Revenue and Forecast, by Drug Class (2017-2030)
13.5.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.5.6.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
13.5.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.5.6.4. Market Revenue and Forecast, by Drug Class (2017-2030)
13.5.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Treatment Type (2017-2030)
13.5.8.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
13.5.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
13.5.8.4. Market Revenue and Forecast, by Drug Class (2017-2030)
13.5.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 14. Company Profiles
14.1. Novartis AG
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Pfizer, Inc.
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Mylan N.V.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. F. Hoffmann La Roche Ltd.
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Eli Lilly And Company
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Merck & Co., Inc.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Teva Pharmaceutical Industries Ltd.
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Celltrion Healthcare Co., Ltd.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Samsung Bioepis
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Bristol Myers Squibb Company
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers